Program (Sep. 20th, morning)

September 20th, Friday

9:00-10:00 Plenary Lecture (Lecture hall)
Session Chair: Takeshi Fuchigami, Kanazawa University

9:00-9:20  PL-01 The Radioisotope Production Network in Korea
   Kyo Chul Lee, Korea Institute of Radiological and Medical
   Sciences
9:20-9:40  PL-02    Recent Progress of Radiopharmaceutical Research
in China
     Zhen Chen, Shanghai Institute of Materia Medica, Chinese
   Academy of Sciences
9:40-10:00  PL-03   Current Status of Radiopharmaceutical Sciences in
      Japan 2024
   Masahiro Ono, Kyoto University

10:00-10:10 Break

10:10-11:00 Oral Session 3 (Lecture hall)
Session Chairs: Yun-Sang Lee, Korea Institute of Radiological
and Medical Sciences
Mengchao Cui, Beijing Normal University

10:10-10:20 O-11 Production of radiometals in medical cyclotron using liquid targets:
     case studies of ^44gSc and ^89gZr
   Yizheng Wang, Chinese Academy of Sciences
10:20-10:30 O-12  Development of stable astatine labeling sites
  Saki Hirata, Kanazawa University
10:30-10:40 O-13  Discovery of novel PET probes targeting CYP11B2 in Aldosterone-
   Producing Adenomas
     Yuki Shimizu, Tohoku University
10:40-10:50 O-14 Development of a novel suitable ¹⁸F-labeled radioligand for imaging
   sigma-1 receptors in brain tumor
       Xu Gao, Beijing Normal University
10:50-11:00 O-15  Design, Preclinical Evaluation, and First-in-Human PET Study of
   [⁶⁸Ga]Ga-PSFA, a FAP/PSMA Heterobivalent Tracer
     Xinlin Wang, Beijing Normal University

11:00-11:10 Break

11:10-12:00 Oral Session 4 (Lecture hall)
Session Chairs: Zhen Cheng, Shanghai Institute of Materia.
Medica, Chines Academy of Sciences
Yasushi Kiyono, University of Fukui

11:10-11:20 O-16  Development of an At-211 labeled RGD peptide with an albumin
   binding moiety and optimization of its pharmacokinetics
    Hiroaki Echigo, Kanazawa University
11:20-11:30 O-17  Theranostic role of Zr-89 and Lu-177-labeled TIM3-targeted
   monoclonal antibody T21 in colon cancer
  Jinping Tao, Peking University Cancer Hospital & Institute
11:30-11:40 O-18  Novel cathepsin B substrate-containing chelating agent to enhance
  intracellular retention of radioimmunoconjugates in tumor
      Hiroki Jinda, Kyoto University
11:40-11:50 O-19  Development of mucin-targeted radionuclide theranostic probes:
   synthesis, characterization and preclinical evaluation
         Jin Ding, Peking University
11:50-12:00 O-20  Development of positively-charged chelating agents that control the
   biodistribution of radioimmunoconjugates
           Kazuma Nakashima, Kyoto University